The Wellcome Trust Case Control and Cardiogenics Consortiums Identify Key Genes in Coronary Artery Disease with Affymetrix (Santa Clara, California) Technology

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that researchers from the Wellcome Trust Case Control Consortium (WTCCC) and the Cardiogenics Consortium have used GeneChip® microarray technology to discover several new genetic variations that may increase the risk of developing Coronary Artery Disease (CAD) by as much as 36 percent. The results of the project were published in the July 18, 2007 issue of the New England Journal of Medicine.